Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in

cladribine
monoclonal antibody therapy
monoclonal antibodies
cancer
rituximab
  • 2 views
  • 23 Jan, 2022
  • 1 location
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated

cladribine
cytarabine
hydroxyurea
neoadjuvant therapy
cancer
  • 19 views
  • 22 Mar, 2022
  • 1 location
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)

The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the

cladribine
nervous
  • 1 views
  • 18 Feb, 2022
  • 1 location
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets

The purpose of this study is to explore the concept that biomarker sensitivity will detect activity in Multiple Sclerosis (MS) subjects and allow appropriate change in treatment to prevent dysfunction.

cladribine
disease or disorder
  • 0 views
  • 24 Mar, 2022
  • 1 location
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

acute myeloid leukemia. Cladribine is a purine nucleoside analog, which has the ability to inhibit DNA synthesis, repair, induce apoptosis, and has anti-leukemia activity for cells in both

cladribine
induction chemotherapy
refractory acute myeloid leukemia (aml)
adult acute myelogenous leukemia
remission
  • 0 views
  • 18 May, 2022
  • 1 location
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) (NOR-MS)

The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific

cladribine
disease or disorder
MRI
rituximab
  • 0 views
  • 15 May, 2022
  • 5 locations
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS)

, particularly Memory B cells, a likely key mechanism of disease control in MS. Cladribine is the investigational product in this study as it not currently used to treat patients with an EDSS of 6.5 - 8.5. This

  • 0 views
  • 30 Jun, 2022
  • 16 locations
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

cladribine
idarubicin
refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
cytarabine
  • 1 views
  • 05 Mar, 2022
  • 1 location
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose, recommended phase 2 dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase …

cladribine
refractory acute myeloid leukemia (aml)
cytarabine
flow cytometry
blast cells
  • 14 views
  • 05 May, 2022
  • 1 location